Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE | PFE Price Prediction). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026. Yet the dividend keeps coming. I want to know if that 7.27% yield is a gift or a warning.
The Dividend at a Glance
Pfizer’s foundational portfolio in oncology, immunology, and cardiovascular care generates non-discretionary demand, and management recently declared its 351st consecutive quarterly payout.
| Metric | Value |
|---|---|
| Annual Dividend | $1.72 |
| Dividend Yield | 7.27% |
| Most Recent Increase | $0.42 to $0.43 (Q1 2025) |
| Aristocrat Status | No (cut in 2009) |
Cash Flow Covers the Dividend, but Just Barely
This is where I get cautious. In 2025, operating cash flow was $11.71 billion and capex was $2.63 billion, leaving free cash flow of $9.08 billion against $9.77 billion in dividends paid. On adjusted earnings, however, the math looks better: full-year adjusted EPS of $3.22 against $1.72 in dividends works out to a 53% payout.
| Metric | TTM | Assessment |
|---|---|---|
| Adjusted Earnings Payout | 53% | Healthy |
| FCF Payout | 108% | Concerning |
| OCF Coverage | 1.20x | Adequate |
Leverage Is the Real Pressure Point
Pfizer carries the Seagen acquisition debt, and it shows. Net debt-to-EBITDA sits at 3.26x, elevated for a pharma major, while interest coverage of 5.78x and debt-to-equity of 0.78 leave room to service obligations. The $7.2 billion cost savings target by end of 2027 matters because it directly defends the payout.
A Streak Reset by 2009, Rebuilt Since
Pfizer cut from $0.32 to $0.16 quarterly in 2009 to fund the Wyeth deal. Since 2010, the dividend has climbed every year, but recent raises are minimal.
| Year | Annual Dividend |
|---|---|
| 2026 | $1.72 |
| 2025 | $1.72 |
| 2024 | $1.68 |
| 2023 | $1.64 |
| 2022 | $1.60 |
Management and Insiders Are Putting Money Where the Mouth Is
CEO Albert Bourla told investors in Q1 2026: “We’re off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer.” Backing that up, 11 directors simultaneously acquired phantom stock units on April 23, 2026 at $26.67 per share, and Bourla himself added six times in three months.
Verdict: Safe, but Watch the Cash Conversion
Dividend Safety Rating: Safe. The earnings payout near 53% is comfortable, growth products like Eliquis, Padcev (+39%), and Vyndaqel (+8%) are scaling, and the Vyndamax patent now runs to June 2031. Pfizer fits an income-oriented thesis if the non-COVID portfolio offsets the $1.5 billion biosimilar headwind. The safety case weakens if FCF coverage stays under 1.0x for another full year, because management cannot lean on the balance sheet forever.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks